Doctors Poulos and Fisher, and the entire team of Dermatologists at Kingsway Dermatology strongly believe that being at the forefront of medical research is a vital part of their practice.
In keeping with our mission to provide outstanding patient care, Kingsway Clinical Research was established in 2014, as a division of Kingsway Dermatology, that specializes in clinical trials in collaboration with Probity Medical Research.
Our goal is to help bring safe and effective cutting edge treatments to our patients. This work allows our patients access to medications, sometimes years ahead of the commercial launch. It also allows our patients access to medications that may not be covered under insurance programs.
Why choose Kingsway Clinical Research?
- Trusted reputation of our team of experienced, Board certified Dermatologists, with experience in clinical trials
- Our research centre is interconnected with a busy dermatology clinic with a large and non-transient patient population
- Conveniently located – right across the Islington subway station, 10 km from St. Joseph’s Hospital, and 12 km from Toronto Pearson International Airport
- Presence of investigators while study patients are scheduled
- Assurance of strictest patient confidentiality, privacy and professionalism
Why volunteer for clinical trials?
- Access to alternative treatments and novel drugs
- Taking an active role in your health care
- Comprehensive medical care from overseeing physician and dedicated clinical trials staff
- Opportunity to contribute to advancements in medical research
- No cost on your part and compensation for travel associated with the study is available
- We are currently accepting patients with moderate to severe Atopic Dermatitis for treatment with a novel medication:
- Evaluation of upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis
- chronic atopic dermatitis with onset of at least 3 years prior to start of study
- history of inadequate response to treatment within 6 months prior to start of study
If you would like to participate and contribute to advancements in medical research or would simply like to learn more, please contact our clinical trials coordinator.
Phone: 416-231-0100 extension 212
Ongoing Trials (enrollment is closed)
- Tralokinumab monotherapy for adults with moderate to severe atopic dermatitis
- Open label, long term extension trial to evaluate the efficacy and safety of tralokinumab in subjects with atopic dermatitis
- Double blind, placebo-controlled study to evaluate the efficacy and safety of barictinib in adults with moderate to severe atopic dermatitis
- Open label, phase 3 study to evaluate efficacy and safety of bariticinib in adults with moderate to severe atopic dermatitis
- Double blind study assessing short and long term efficacy, safety and tolerability of secukinumab in subjects of body weight 90 kg or higher with moderate to severe plaque psoriasis
- Phase 3 open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque psoriasis
- A Phase 3 Efficacy and safety study of Taparinof for the treatment of plaque psoriasis in adults
- A safety and efficacy study to compare dapsone dermal gel with vehicle control in patients with acne vulgaris
- Double blind, vehicle-controlled Phase IIb study to assess the safety and efficacy of topically applied DS107 cream in mild to moderate atopic dermatitis
- Phase 3 confirmatory study investigating efficacy and safety of dupilumab monotherapy in adults with moderate to severe atopic dermatitis
- Phase 3 double blind, placebo-controlled study investigating the efficacy and safety of multiple dupilumab dose regimens for maintaining response in patients with atopic dermatitis
- Open label study of dupilumab in patients with atopic dermatitis
- Canadian Humira post-marketing observational epidemiological study assessing effectiveness in psoriasis
- Phase 3 study to evaluate the efficacy and safety of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis
- Open label study to assess the safety of etanercept in subjects with plaque psoriasis
- Risankizumab versus placebo in patients with moderate to severe plaque psoriasis
- Double blind study of secukinumab to demonstrate efficacy compared to ustekinumab in subjects with moderate to severe plaque psoriasis
- Double blind, active-control study to compare efficacy and safety of CHS-1420 versus Humira in subjects with chronic plaque psoriasis